此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

使用 89Zr-DFO-REGN5054 对接受 Cemiplimab 治疗的实体癌成人参与者进行 ImmunoPet 成像研究

2026年10月19日 更新者:Regeneron Pharmaceuticals

89Zr-DFO-REGN5054(抗 CD8)正电子发射断层扫描在接受 Cemiplimab 治疗的实体恶性肿瘤患者中的首次人体研究

This study is researching an experimental drug called 89Zr-DFO-REGN5054 and cemiplimab. The study is focused on patients with a type of cancer that can be potentially imaged using 89Zr-DFO-REGN5054 and show special tumor features that may be important to the way the immune system fights cancer.

The aim of the study is to study the safety and tolerability (how the body reacts to the drug) of the imaging agent 89Zr-DFO REGN5054.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drugs
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drugs (which could make the study drugs less effective or could lead to side effects)

研究概览

研究类型

介入性

注册 (实际的)

22

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Groningen、荷兰、9700 RB
        • UMC Groningen

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  • Advanced or metastatic solid tumors that may respond to anti-programmed cell death 1 (PD-1) immunotherapy
  • Measurable disease according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤1
  • Adequate organ and bone marrow function as defined in the protocol
  • Willing and able to comply with clinic visits and study-related procedures (including required tumor biopsy for Part B)

Key Exclusion Criteria:

  • Currently receiving another cancer treatment or inadequate time since last therapy, as defined in the protocol
  • Has not yet recovered from acute toxicities from prior therapy; exceptions defined in the protocol
  • Prior treatment with a blocker of the PD-1/Programmed death ligand 1 (PD-L1) pathway
  • Currently receiving or has received chimeric antigen receptor (CAR-T) cell therapy
  • Symptomatic or untreated brain metastases, leptomeningeal disease, or spinal cord compression
  • Known history of or any evidence of interstitial lung disease, active, noninfectious pneumonitis (past 5 years) or active tuberculosis

NOTE: Other protocol defined inclusion/exclusion criteria apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Single ascending dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab

Part A:

Doses of 89Zr˗DFO˗REGN5054 may be reduced based upon assessment.

Administered by intravenous (IV) infusion during Part A and B.

Administered by IV infusion every 3 weeks (Q3W).

其他名称:
  • REGN2810
  • 利布塔约
实验性的:Defined dose of 89Zr˗DFO˗REGN5054 followed by fixed dose of cemiplimab

Part B:

Defined dose of 89Zr˗DFO˗REGN5054 determined in Part A.

Administered by intravenous (IV) infusion during Part A and B.

Administered by IV infusion every 3 weeks (Q3W).

其他名称:
  • REGN2810
  • 利布塔约

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence and severity of treatment-emergent adverse events (TEAEs)
大体时间:Up to day 8, after the infusion of 89Zr˗DFO˗REGN5054

Part A

Up to day 8, after the infusion of 89Zr˗DFO˗REGN5054
Incidence and severity of TEAEs
大体时间:Up to approximately week 115

Part A and B

Up to approximately week 115

次要结果测量

结果测量
措施说明
大体时间
Clinical dosimetry based on tissue radiation absorbed dose calculated from positron emission tomography (PET) image acquisition data
大体时间:On days 1, 5 and 8

After injection of 37 megabecquerel (MBq) of 89Zr-DFO-REGN5054, a series of whole-body positron emission tomography (PET) images will be obtained over a period of up to 8 days and corrected for attenuation by low-dose computed tomography (CT) scans using PET/CT. The radiation effective dose per organ/tissue will be calculated for each organ using Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA/EXM). The unit of effective dose per organ/tissue will be millisievert per Minimum Base Quantity (MBq) for each participant's organ/tissue. The final values for each organ will be averaged across participants for each mass dose

On days 1, 5 and 8
Clinical dosimetry based on tissue radiation effective dose calculated from PET image acquisition data
大体时间:On days 1, 5 and 8

After injection of 37 MBq of 89Zr-DFO-REGN5054, a series of whole-body PET images will be obtained over a period of up to 8 days and corrected for attenuation by low-dose CT scans using PET/CT. The radiation effective dose for the whole body will be calculated using OLINDA/EXM software. The unit of effective dose will be millisievert per MBq for the whole body for each participant. The final values will be averaged across participants for each mass dose.

On days 1, 5 and 8
Concentration of 89Zr-DFO-REGN5054 in serum
大体时间:On days 1, 5 and 8

Part A

On days 1, 5 and 8
Serum imaging agent activity concentration of area under the curve (AUC0-7)
大体时间:Up to day 8

Part A

Up to day 8
89Zr-DFO-REGN5054 uptake across cluster of differentiation 8 (CD8)-expressing normal tissues and tumors
大体时间:At the time of imaging, up to day 8

Part A and Part B

At the time of imaging, up to day 8
Blood pool uptake of 89Zr-DFO-REGN5054 with subsequent calculation of standardized uptake value (SUV) tumor-to-blood ratios
大体时间:At the time of imaging, up to day 8

Part A and Part B

At the time of imaging, up to day 8
Association of 89Zr˗DFO˗REGN5054 autoradiographic signal intensity distribution with CD8 expression in tumor tissues
大体时间:At Baseline

Part A and Part B

At Baseline
Association of 89Zr-DFO-REGN5054 uptake with CD8 expression in tumor tissues
大体时间:At Baseline

Part B

At Baseline
Association of tumor-to-blood ratio of 89Zr-DFO-REGN5054 with CD8 expression in tumor tissues
大体时间:At Baseline

Part B

At Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Trials Management、Regeneron Pharmaceuticals

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年2月7日

初级完成 (估计的)

2027年4月29日

研究完成 (估计的)

2027年4月29日

研究注册日期

首次提交

2022年1月24日

首先提交符合 QC 标准的

2022年2月22日

首次发布 (实际的)

2022年2月28日

研究记录更新

最后更新发布 (实际的)

2026年10月20日

上次提交的符合 QC 标准的更新

2026年10月19日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • R5054-ONC-1843
  • 2019-001604-38 (EudraCT编号)
  • 2019 (美国 NIH 拨款/合同)
  • 2024-515351-37-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD 共享时间框架

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD 共享访问标准

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅